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A B S T R A C T
Background
Epilepsy affects approximately 1% of the population, with up to 30% of patients continuing to have seizures, despite antiepileptic drug
treatment. Clobazam is a 1,5-benzodiazepine and is commonly used as an add-on treatment for drug-resistant epilepsy. This review is an
updated version of the original Cochrane Review, first published in 2008, and examines the most current literature regarding clobazam
as an add-on for drug-resistant epilepsy.
Objectives
To assess the efficacy, effectiveness and tolerability of clobazam as an add-on therapy for drug-resistant generalised-onset and focal-onset
seizures, with or without secondary generalisation, in adults and children.
Search methods
For the latest update, we searched the following databases on 9 October 2018: Cochrane Register of Studies (CRS Web), which includes
the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), Medline (Ovid) 1946
to 8 October, 2018, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP). For some previous updates we
also searched SCOPUS, DARE, and BIOSIS Previews, but these are no longer needed. (SCOPUS was searched as a substitute for EMBASE,
but randomised and quasi-randomised controlled trials in EMBASE are now included in CENTRAL; DARE ceased operation at the end of
March 2015; BIOSIS Previews yielded no relevant items that were not found in the other databases).
Selection criteria
Randomised trials of add-on clobazam, with adequate methods of allocation concealment, recruiting patients with drug-resistant focal
or generalised-onset seizures, with a minimum treatment period of eight weeks.
Data collection and analysis
Two review authors independently selected trials for inclusion and extracted relevant data. The following outcomes were assessed: 50%
or greater reduction in seizures, seizure freedom, treatment withdrawal and adverse events.
Main results
Four double-blind, placebo-controlled, cross-over studies, representing 197 participants, were included in the review. All four studies were
assessed as having unclear risk of bias due to the unavailability of methodological details. The studies demonstrated significant method-
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ological heterogeneity and differences in outcome measures were noted. Consequently, it was not possible to summarise the data in a
meta-analysis. Instead, findings were summarised in a narrative data synthesis, Only two of the studies reported 50% or greater seizure
reduction. They respectively reported that 57.7% and 52.4% of participants receiving add-on clobazam experienced a 50% or greater re-
duction in seizure frequency, although publication bias needs to be considered (2 RCTs, n = 47, very low-quality evidence). Seizure freedom
was reported by three of the included studies. Collectively, 27 out of 175 patients were seizure-free during treatment with clobazam (3
RCTs, n = 175, very low-quality evidence). Two studies specifically stated that seizure freedom was not observed in any of the participants
receiving add-on placebo. Treatment withdrawal was reported by all four studies. There was a slightly higher incidence of treatment with-
drawal associated with receiving clobazam, although the overall incidence was still fairly low (4 RCTs, n = 197, very low-quality evidence).
Adverse events were only described in two of the studies, reportedly 36% and 85% of participants experienced one or more adverse events
whilst receiving clobazam. The most commonly reported adverse event was drowsiness.
Authors' conclusions
Clobazam as an add-on treatment may reduce seizure frequency and may be most effective in focal-onset seizures. It is important to
recognise that this finding has been derived from very low-quality evidence and from studies judged to have an unclear risk of bias. It
remains unclear which population demographic will best benefit from clobazam and over what time-frame. A large-scale, randomised
controlled trial, conducted over a greater period of time, incorporating subgroups with differing seizure types, is required to effectively
inform clinical practice.
P L A I N   L A N G U A G E   S U M M A R Y
Clobazam as an add-on treatment in the management of drug-resistant epilepsy
Background
Epilepsy is a disorder of repeated seizures. Whilst many people will achieve freedom from seizures on one antiepileptic medication, some
may require multiple medications to try to reduce the number of seizures that they have. These people are said to have drug-resistant
epilepsy.
Aim of the review
Clobazam is an antiepileptic medication. Here, we examine the evidence from medical studies to determine how effective clobazam is at
reducing the number of seizures that people have when used as an add-on treatment by people with drug-resistant epilepsy.
Results
We found four studies which had assessed clobazam as an add-on treatment for drug-resistant epilepsy. They included a total of 197
people. Two studies reported that more than half of the people given clobazam reached a 50% of greater reduction in the number of their
seizures. Three of the studies reported how many people were seizure-free whilst taking clobazam. In total, approximately 15% of people
were seizure-free when taking clobazam, compared to 0% when they were given placebo (a fake, inactive drug which should have no effect
of epilepsy). All four studies reported how many people withdrew from treatment during the studies. Slightly more people withdrew from
the studies when receiving clobazam (17 out of 197 people) than when receiving placebo (12 out of 197 people), but the rate of people
withdrawing was still low overall. Clobazam was associated with side effects, in particular drowsiness.
All four studies were of short duration. They used different methods, e.g. different lengths of treatment, and were of poor quality. The
results suggest that clobazam reduces seizure frequency for people with drug-resistant focal epilepsy (epilepsy that originates from one
area of the brain), but there were not enough data to determine whether clobazam is as effective for generalised epilepsy (epilepsy involv-
ing the whole brain). The very low quality of the evidence provided by the four included studies means that we are very uncertain about
whether the findings are accurate and, therefore, they must be taken and applied with caution.
The evidence is current to October 2018.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Clobazam compared to Placebo in the management of drug-resistant epilepsy
Clobazam compared to Placebo in the management of drug-resistant epilepsy




Anticipated absolute effects* (95% CI)Outcomes













Follow up (range): 9
weeks to 12 weeks
In both studies, more than half of the patients experienced a
50% or greater reduction in seizure frequency when receiving
clobazam. One study reported that a significantly larger propor-
tion of patients received a 50% or greater reduction whilst receiv-
ing clobazam, compared to placebo, whilst the other specifically





VERY LOW 1, 2
Clobazam may in-
crease the likelihood
of a 50% or greater re-
duction in seizure fre-
quency but we are very
uncertain.
Seizure Freedom
Follow up (range): 8
weeks to 12 weeks
3 studies reported that multiple patients (27/175, collectively)
achieved seizure freedom when receiving clobazam. Two stud-
ies specifically stated that no patients achieved seizure freedom
when receiving placebo. One study did not report the incidence of












Follow up (range): 8
weeks to 12 weeks
All 4 studies reported treatment withdrawal. 2 studies reported a
higher occurrence of treatment withdrawal during the clobazam
arm compared to the placebo arm (5/26 vs. 1/26 participants and
2/21 vs. 0/21 participants for each study, respectively), one report-
ed a higher prevalence during placebo (11/129 vs. 10/129 partici-
pants). The fourth study did not specify which arm the patient was




VERY LOW 1, 2
Clobazam may slight-
ly increase the risk of
treatment withdrawal
but we are very uncer-
tain.
Treatment withdraw-
al due to adverse
events
Follow up: 12 weeks
Two studies reported incidence of treatment withdrawal due to
AEs during the clobazam treatment arm (2/21 and 3/129). No pa-




VERY LOW 1, 2
Clobazam may in-
crease treatment with-
drawal due to adverse










































































































































This outcome was not reported by any of the included studies and
could not be calculated from the available data.
- - -  




This outcome was not reported by any of the included studies and
could not be calculated from the available data.
- - -  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Evidence was downgraded once with regard to the risk of bias domain because the included studies lacked methodological details leading to an unclear risk of bias judgement.
No information was provided regarding funding.
2 Evidence was downgraded once with regard to imprecision due to the narrative synthesis conducted and the subsequent absence of an estimated effect size. Evidence was
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B A C K G R O U N D
This is an updated version of the Cochrane Review first published
in 2008 (Michael 2008)
Description of the condition
Epilepsy is a common condition affecting 1% of the population.
Although many advances have been made in the management of
people with epilepsy, a significant proportion of the population, up
to 30% in some studies, continue to experience seizures drug-re-
sistant to even multiple combinations of antiepileptic drugs (AEDs)
(Cockerell 1995). Whilst there is no unifying definition of 'drug-resis-
tant' epilepsy, most definitions refer to continued seizures despite
antiepileptic drug treatment. The generally employed definition
is of continued seizures despite interminable medication changes
(French 2006).
Description of the intervention
The 1,4-benzodiazepines, such as diazepam, have a clear role in the
acute management of epileptic seizures. The 1,5-benzodiazepine
clobazam has long been used as an add-on treatment to reduce
seizure frequency (since having been initially investigated by Gas-
taut and colleagues in 1979, once it had come oG patent (Gastaut
1979)).
How the intervention might work
Animal studies suggest that the difference in clobazam's chemical
structure, and that of its active metabolite N-desmethyl-clobazam,
give it a broader spectrum of antiepileptic activity, inhibiting the
spread of seizures and increasing the seizure threshold, compared
to the classical benzodiazepines. Further disadvantages to the use
of 1,4-benzodiazepines, for example, the retention of diazepam in
fat stores and the short half-life of lorazepam, are not encountered
with clobazam as the half-life of the active metabolite is between
35 and 133 hours, resulting in a steady relative concentration of
clobazam:N-desmethyl-clobazam of 1:8. Furthermore, there is re-
tention of the diazepam ring following metabolisation (Robertson
1995).
Why it is important to do this review
Whilst concerns have been raised regarding the long-term use of
clobazam, with regard to adverse events such as sedation and the
development of tolerance, the only data to support these claims
come from open, non-randomised trials, with widely ranging vari-
ation in the definition of 'tolerance'. The largest and most often
cited trial was retrospective (CCCG 1991). Furthermore, the seda-
tive, muscle-relaxant and behavioural effects are reported to be
less marked than with diazepam and the other classical benzodi-
azepines (Kruse 1985). In addition, there has been some suggestion
that, when used in conjunction with other AEDs, such as when man-
aging cases of drug-resistant epilepsy, there may be additive effica-
cy without additive toxicity. This may, in part, be due to increased
concentrations of the active metabolite, N-desmethyl-clobazam,
due to the induction of hepatic enzymes by the other AEDs (Guber-
man 1998; Theis 1997).
The aim of this review is to examine the efficacy of clobazam as
an add-on treatment in the management of drug-resistant cases of
epilepsy, of focal-onset seizures, with or without secondary gener-
alisation, and generalised tonic-clonic seizures, in both adults and
children, with regard to seizure reduction, adverse events and tol-
erance.
O B J E C T I V E S
To assess the efficacy, effectiveness and tolerability of clobazam as
add-on therapy for drug-resistant generalised-onset and focal-on-
set seizures, with or without secondary generalisation, in adults
and children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies were included if they satisfied the following criteria:




4. parallel group or cross-over studies;
5. have a minimum treatment period of eight weeks.
Types of participants
Children (< 16 years) or adults with drug-resistant generalised or
focal-onset seizures (including simple focal, complex focal or sec-
ondary generalised seizures).
Types of interventions
1. The active treatment group received clobazam in addition to
their usual antiepileptic drugs (AED) treatment.
2. The control group received placebo in addition to their usual
AED treatment.
Types of outcome measures
Primary outcomes
E7icacy measures
1. FiHy per cent or greater reduction in seizure frequency
The proportion of participants with a 50% or greater reduc-
tion in seizure frequency in comparison to the pre-randomisation
baseline period for the entire study population and for each of
the seizure subgroups, partial-onset and generalised-onset, ton-
ic-clonic seizures. This outcome was chosen as it is commonly re-
ported in this type of study and can be calculated for studies that
do not report this outcome, provided baseline data are recorded.
2. Seizure freedom





The proportion of participants having their treatment withdrawn
during the course of the treatment period, representing a measure
of "global effectiveness". Treatment may be withdrawn due to ad-
verse events, lack of efficacy or a combination of both.
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Tolerability measures
1. Treatment withdrawal due to adverse events
The proportion of individuals experiencing adverse events requir-
ing medication withdrawal.
2. Adverse events
The proportion of individuals experiencing any of the following ad-
verse events, considered by the review authors to be common and








Quality of life measures
We summarised data on quality of life outcomes from any validated
study in this review.
Tolerance measures
We summarised data on the development of antiepileptic drug tol-
erance, and the definitions used in each study, in this review.
Search methods for identification of studies
Electronic searches
Searches for the original Cochrane Review (Michael 2008) were run
in March 2007. Subsequent searches were run in June 2010, Feb-
ruary 2011, November 2012, January 2015, and April 2016. For this
latest update the following databases were searched on 9 October
2018, with no language restrictions.
1. Cochrane Register of Studies (CRS Web), which includes the
Cochrane Epilepsy Group Specialized Register and the Cochrane
Central Register of Controlled Trials (CENTRAL), using the search
strategy set out in Appendix 1.
2. Medline (Ovid) 1946 to 08 October 2018, using the search strate-
gy set out in Appendix 2.
3. ClinicalTrials.gov, using the search strategy set out in Appendix
3.
4. WHO International Clinical Trials Registry Platform (ICTRP), us-
ing the search strategy set out in Appendix 4.
For the previous update, we also searched SCOPUS, DARE, and
BIOSIS Previews, but these are no longer needed. (SCOPUS was
searched as a substitute for Embase, but randomised and qua-
si-randomised controlled trials in Embase are now included in CEN-
TRAL; DARE ceased operation at the end of March 2015; BIOSIS Pre-
views yielded no relevant items that were not found in the other
databases).
Searching other resources
In addition, we checked reference lists from the identified trials for
other relevant articles.
Information about the searches carried out for the original version
of this review ((March 2007) is in Appendix 5.
Data collection and analysis
Selection of studies
Two review authors independently assessed trials for inclusion. We
compared results and resolved any disagreements by discussion.
Data extraction and management
We obtained the following information, where available, for each
trial meeting our inclusion criteria.
Trial design
1. Sampling method
2. Inclusion and exclusion criteria
3. Method of diagnosis of epilepsy
4. Method of randomisation
5. Method of concealment of randomisation
6. Method of blinding
7. Method of tablet aesthetics matching
8. Stratification factors
9. Duration of baseline period
10.Duration of treatment period
11.Duration of 'wash-out' period in cross-over studies




3. How the diagnosis of epilepsy made
4. Seizure type(s)
5. Number and generic names of background AEDs
6. Seizure frequency prior to randomisation
7. Presence of neurological deficit/signs at baseline
8. Co-morbidities
9. Electroencephalogram (EEG) results at baseline
10.Neuroimaging computerised tomography (CT)/magnetic reso-
nance imaging (MRI) scans
Treatment data
1. Medication dose per treatment group
2. Protocol for dosage increase and decrease
3. Total number of participants allocated to each group
Follow-up
1. The number of individuals in each group achieving a 50% or
greater reduction in seizures per treatment group
2. The number of individuals in each group achieving total cessa-
tion of seizures
3. Where possible to ascertain, demographic factors and seizure
types in relation to seizure reduction or cessation
4. The number of individuals having treatment withdrawn and rea-
sons for withdrawal per treatment group
5. Participants missing in the data
Clobazam add-on therapy for drug-resistant epilepsy (Review)
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6. For those excluded, the reason for exclusion, whether any of
the excluded participants completed the treatment phase and
whether any of those had a 50% reduction in seizure frequency
during the treatment phase
Outcomes
Efficacy, tolerability, adverse events and tolerance, as listed above,
per randomisation group.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of the
included studies using the 'Risk of bias' tool, as recommended
by the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Studies were assessed according to six parame-
ters: method of randomisation, allocation concealment, method of
blinding, incomplete outcome data, selective outcome reporting
and other potential sources of bias. For each parameter, studies
were awarded either a 'low risk' of bias, a 'high risk' of bias or an
'unclear risk' of bias. Each judgment was justified by either a quote
taken directly from the text or by a comment from the review au-
thors, describing the study design, which led to the judgment being
made.
Measures of treatment e7ect
We proposed to use risk ratios (RR) with 95% confidence intervals
(CIs) to represent the primary and secondary efficacy outcomes. Al-
ternatively, we intended to use 99% confidence intervals (CIs) to re-
port the incidence of individual adverse events to permit multiple
testing.
Unit of analysis issues
Cross-over studies introduce unit of analysis issues. Our intention
was that if the cross-over study was well-conducted and method-
ologically sound, then the whole data set would be used. For those
studies with problems, then only data from the first treatment pe-
riod would be used.
Dealing with missing data
We planned to perform an intention-to-treat analysis of partici-
pants according to their treatment allocation, regardless of the
final treatment that participants received. Consequently, partic-
ipants not completing follow-up, or with inadequate seizure da-
ta, would have been considered to be non-responders. The inten-
tion-to-treat approach was still adopted for the descriptive analy-
sis utilised.
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by compar-
ing the distribution of important participant factors between tri-
als (age, seizure type, duration of epilepsy, number of antiepileptic
drugs taken at time of randomisation) and trial factors (randomisa-
tion, concealment, blinding and losses to follow-up).
We planned to assess statistical heterogeneity by using a Chi2 test
with the I2 statistic where P < 0.05 indicates significant heterogene-
ity. Specifically, with regard to the I2 statistic: 0% to 40% would
have indicated heterogeneity which might not have been impor-
tant, 30% to 60% would have possibly indicated moderate het-
erogeneity, 50% to 90% may have represented substantial hetero-
geneity, and 75% to 100% would have implied considerable het-
erogeneity. If heterogeneity had been found then potential caus-
es would have been explored. In the absence of significant hetero-
geneity, we would have synthesised data using a fixed-effect mod-
el.
Assessment of reporting biases
We requested the trial protocol for each of the included studies to
enable us to identify whether there had been any reporting bias
with regards to the efficacy and safety outcomes of the studies. We
proposed to investigate publication bias by examining funnel plots.
This method was, however, hindered by the low number of studies
identified for inclusion.
Data synthesis
In the case of low heterogeneity, as determined using the Chi2 test,
we originally proposed to use a fixed-effect model meta-analyses
for data synthesis, using the Mantel-Haenszel risk ratio (RR) with
95% confidence intervals (CIs) . Where possible, we planned to
analyse participants according to seizure type. Unfortunately, on-
ly one study provided data relevant to the efficacy outcomes, and
consequently, we were unable to complete any meta-analysis. We
instead employed a narrative data synthesis. Notably, for some
outcome measures, a narrative interpretation of the data had al-
ready been planned; i.e. to summarise the data collected on toler-
ance and quality of life.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses according to age (children versus
adults), seizure type (generalised versus focal-onset seizure) and
severity at baseline (according to seizure frequency at baseline as
this baseline characteristic is commonly reported). However, we
were unable to execute any of the planned subgroup analyses.
Sensitivity analysis
We did not plan to conduct any sensitivity analyses.
Summarising and interpreting results
We used the GRADE approach, as outlined in the GRADE Handbook
(Schünemann 2013), to interpret findings, and GRADEpro GDT soft-
ware (which imports data from Review Manager 5 software (GRADE-
pro GDT 2015)), to create a 'Summary of findings' table for the fol-
lowing outcomes, deemed to be the most important: 50% reduc-
tion in seizure frequency, seizure freedom, treatment withdrawal,
treatment withdrawal due to adverse events, 50% reduction in gen-
eralised-onset seizure frequency, and 50% reduction in focal-onset
seizure frequency.
Notably, the outcomes, 50% reduction in generalised-onset seizure
frequency and 50% reduction in focal-onset seizure frequency,
were not reported by any of the included studies and, therefore,
could not be described in the narrative review. We still included
both outcomes in the 'Summary of findings' table to remain trans-
parent about these outcomes.
R E S U L T S
Description of studies
Results of the search
The search strategies used revealed a total of 349 records for po-
tential inclusion. One hundred and eleven duplicate records were
Clobazam add-on therapy for drug-resistant epilepsy (Review)
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removed. An additional 225 records were excluded due to their ir-
relevance. The full-text articles were obtained for the remaining 13
records to assess their eligibility for inclusion. We excluded another
nine full-text articles for various reasons, as listed in Figure 1. Four
studies remained eligible for inclusion in the review and were con-
sequently used to formulate a descriptive analysis.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
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Included studies
The total number of participants included was 197. Details of the in-
cluded studies are reported in the Characteristics of included stud-
ies table.
The study conducted by Allen 1983 was a double-blind, ran-
domised, placebo-controlled, cross-over trial. The treatment/con-
trol period lasted nine weeks with an eight-week wash-out period
between arms. The clobazam dosage employed was 30 mg at night
for all participants, equivalent to 0.5 mg/kg, presuming a mean par-
ticipant weight of 60 kg. The other AEDs being taken during the
study period were carbamazepine, phenytoin, phenobarbitone and
sodium valproate. The study sample size was limited with only 26
participants, of mean age 34 (range 18 to 60). The study includ-
ed both participants with generalised- and focal-onset seizures, al-
though the exact numbers of participants with each seizure type
was not specified.
Keene 1990 was also a small, double-blind, randomised, place-
bo-controlled, cross-over study, recruiting 21 participants, aged 2
to 19 years (mean 11 years, number over 16 years undisclosed).
At baseline, thirteen participants had generalised-onset seizures
and eight had focal-onset seizures. Following an initial one-month
baseline period, participants were assigned to a sequence of place-
bo-clobazam or clobazam-placebo. Treatment periods were of
three months with a one-month wash-out period. The initial dosage
of clobazam was calculated as 0.5 mg/kg on commencement, in-
creased to 1 mg/kg if no response was achieved. Furthermore, were
the participants to develop excessive drowsiness, the dosage was
decreased by 0.25 mg/kg/day. Although they do state that baseline
serum AED levels were taken and doses adjusted to achieve thera-
peutic levels, there is no report as to which AEDs were being taken
at baseline.
The only multi-centre trial identified was conducted by Koeppen
1987 and took place across five European countries. This was also a
randomised, placebo-controlled, cross-over study and was report-
ed as being double-blind. This was the largest of the studies identi-
fied, recruiting 129 participants, of which, 63 were randomised to
clobazam then placebo and 66 to placebo then clobazam. There
was a one-month baseline period and each 'treatment' period
was of three months duration with a one-month wash-out peri-
od. Clobazam doses ranged from 10 to 40 mg/day, equating to a
dosage range of 0.17 to 0.67 mg/kg, presuming a mean partici-
pant weight of 60 kg. The baseline AEDs being taken were, in order
of decreasing frequency: carbamazepine, phenobarbital, pheny-
toin, valproate and primidone. The baseline seizure types were 32
of generalised-onset and 149 of focal-onset, during the preceding
year.
The fourth study, Schmidt 1986, was also a randomised, dou-
ble-blind, placebo-controlled, cross-over study. The sample size
was limited, involving only 21 participants aged between 18 and
55 years (mean 38 years). The dosage of clobazam used was 10 mg
three times a day, increasing to a maximum of 40 mg three times
a day in 10 mg increments in the first month. The maximum dose
was continued for months two and three. Clobazam was then de-
creased by 5 to 10 mg stages over the 4th month. The placebo was
increased and decreased following the same guide, thus creating a
gradual wash-out period over one month. This resulted in a mean
dose of 0.54 mg/kg (range 0.23 to 0.74 mg/kg). The study concluded
with a one-month observation period, during which both clobazam
and placebo were removed. The baseline AEDs being taken were, in
order of decreasing frequency: phenytoin, carbamazepine, primi-
done, phenobarbital, valproic acid, mephenytoin and clonazepam.
The baseline seizure types were six of generalised onset and 29 of
focal onset. It was not stated if this was during the one-month ob-
servation period or another time-frame.
Excluded studies
A total of 9 studies (Andrade 2009; Basu 2007; Conry 2009;
NCT02134366; NCT02564952; NCT02565108; NCT02726919; Semah
2014; Vajda 1985) were excluded from the review. The reasons for
exclusions are provided in the Characteristics of excluded studies
table.
During the initial search in March 2007, one study (Vajda 1985)
was excluded. Despite the study being a randomised, controlled
trial with cross-over design, investigating clobazam as an add-on
for drug-resistant epilepsy, the study was a pilot study with on-
ly a three-day treatment period, followed by a longer-term cross-
over study of only four weeks, with no wash-out period. It there-
fore, did not satisfy the inclusion criteria that specified that stud-
ies must have a minimum treatment period of eight weeks du-
ration. Furthermore, only nine participants were randomised, of
which, four were later transferred to an open trial. Only prelimi-
nary results were presented and these incorporated open, non-ran-
domised participants. No standard follow-up period or outcome
measures were described. Additionally, for the five participants
in the randomised phase, no data were presented to determine
seizure frequency or 50% reduction. The full study report was not
published.
An updated search in November 2012 identified three additional
studies (Andrade 2009; Basu 2007; Conry 2009) for potential inclu-
sion.The studies were not, however, applicable for inclusion be-
cause: one study investigated as clobazam as a monotherapy (An-
drade 2009), one was open-label and therefore did not suffice the
blinding inclusion criteria (Basu 2007), and one had a treatment pe-
riod shorter than 8-weeks in duration (Conry 2009)
An updated search in 2016 identified one further potentially eligi-
ble study (Semah 2014). This study was not applicable for inclusion
because it was an open-label study and thus lacked any method of
blinding.
During the latest update, the four studies, previously classified
as ongoing studies (NCT02134366; NCT02564952; NCT02565108;
NCT02726919), were reclassified as excluded studies. Notably, two
of the studies (NCT02564952; NCT02726919) were identified to be
open-label extension studies with single-group assignment, thus
making the studies ineligible for inclusion in the review. Anoth-
er study (NCT02134366) had been terminated due to recruitment
issues, resulting from a limited target population. Consequently,
there were no results available for inclusion in the review. For the
remaining study (NCT02565108), we noted that both treatment
groups received clobazam. The intervention treatment group re-
ceived clobazam in combination with cannabidiol, whilst the con-
trol group received clobazam with add-on placebo. The study,
therefore, did not satisfy the inclusion criteria.
Risk of bias in included studies
The results from the 'Risk of bias' assessment for the four included
studies are summarised in Figure 2 and Figure 3. The individual do-
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main ratings for each study can be found in the 'Risk of bias' tables,
linked to the Characteristics of included studies tables. All four in-
cluded studies were judged to have an unclear risk of bias, largely
due to the incomplete reporting of the trial methodology, supplied
in the full-text articles.
 
Figure 2.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
Three of the included studies failed to adequately describe both the
method used to generate the randomisation sequence, as well as
the method for allocation concealment. The multicentre study by
Koeppen 1987 reported that the randomisation method was differ-
ent for each centre, however, the specific methods for each cen-
tre were not disclosed. All three studies were therefore awarded an
unclear risk of bias for both parameters, random sequence genera-
tion and allocation concealment.In contrast, Keene 1990 did state
that the hospital pharmacy was responsible for treatment alloca-
tion whilst a blinded pharmacist was responsible for dispensing the
study drug and was thus awarded a low risk of selection bias. Keene
1990 did not, however, provide any details on how the randomisa-
tion sequence was generated and, consequently, we judged that
Keene 1990 remained at unclear risk of bias for this domain.
Blinding
Two studies, Allen 1983 and Schmidt 1986, effectively described
their methods of blinding. Matching placebo was given to partic-
ipants to ensure the blinding of both participants and study per-
sonnel. In both studies, participants self-reported their seizure fre-
quency and adverse events, and therefore, acted as the outcome
assessors. As a result, the outcome assessors were, likewise, effec-
tively blinded. Furthermore, study personnel, including those re-
sponsible for data entry and data analysis would, likewise, have
been adequately blinded throughout their study involvement. The
risk of bias for Allen 1983 and Schmidt 1986 was thus rated as low
for both performance and detection bias. Conversely, Keene 1990
and Koeppen 1987 did not provide details of how the blinding of
participants and study personnel was achieved. Both studies con-
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sequently received an unclear risk of bias rating for performance
and detection bias.
Incomplete outcome data
The risk of bias associated with attrition varied between the four
studies. The study by Allen 1983 was judged to have a low risk of
bias. Attrition was declared as the study reported that six partic-
ipants withdrew during the trial. Additional analysis was carried
out whereby all participants who withdrew from the study were in-
cluded in the statistical analyses and were classified as non-respon-
ders,thus, intention-to-treat analysis had been performed. Similar-
ly, Keene 1990 reported that two participants withdrew from the
study. The results reported, however, included the total number
of randomised participants, thus implying that intention-to-treat
analysis had been conducted. Keene 1990 was likewise awarded a
low risk of bias, with respect to attrition. In contrast, whilst Koep-
pen 1987 revealed that 21 participants withdrew from the study
and another two participants provided incomplete outcome data,
thereby reporting the attrition rate, Koeppen 1987 did not, howev-
er, compute efficacy data from these participants and, therefore,
did not account for them in the analysis. As a result, intention-to-
treat analysis was not performed and the study was deemed to
have a unclear risk of attrition bias. Similarly, Schmidt 1986 report-
ed that one participant was excluded from the study following ran-
domisation, due to non-compliance regarding seizure count and
tablet count. No information was provided as to which treatment
group the participant belonged to when they were withdrawn, and
moreover, the participant was excluded from any efficacy analysis.
Consequently, intention-to-treat analysis was not conducted. Sch-
midt 1986 was, likewise, awarded an unclear risk of bias rating for
attrition bias.
Selective reporting
All four studies (Allen 1983; Keene 1990; Koeppen 1987; Schmidt
1986) failed to supply a trial protocol for the 'Risk of bias' assess-
ment. The four studies were judged to have unclear risk of bias
with respect to selective reporting. Three of the studies, Allen 1983;
Koeppen 1987 and Schmidt 1986, neglected to define any specific
efficacy outcomes within the methods sections of their texts. It was
therefore unclear whether all intended outcomes had been mea-
sured and reported within the respective results sections. In con-
trast, the remaining study, by Keene 1990, specified in the methods
section of their article that their efficacy outcome of interest was a
50% or greater reduction in seizure frequency. The results for this
outcome were then fully reported within the results section of the
text. We, however, suspect that this was not the only outcome in-
tended to be measured and would expect that the study would al-
so have at least recorded adverse events. We thus deemed it likely
that there was selective reporting in this study and similarly award-
ed this study an unclear risk of bias for reporting bias.
Other potential sources of bias
In the study by Allen 1983, participants were assessed for baseline
seizure rates for an undisclosed period of time and were defined
as being 'drug-resistant' although there was no description of how
the diagnosis of epilepsy had been made. Participants were thus
included if they were having four or more uncontrolled seizures a
month. Moreover, there was no information provided as to the ex-
act number of participants with each baseline seizure type, these
being generalised-onset and focal-onset seizures, which were lat-
er described within the results taken from the two treatment peri-
ods. No exclusion criteria were presented. Additionally, there was
no description of any adjustment of the dosage. Notably, however,
whilst the mean serum clobazam concentration, taken during the
last three weeks of treatment, was 0.33 µmol/L, there was a wide
range (0.13 µmol/L to 0.99 µmol/L). This could indicate either: a
wide range of participant-dependent pharmacokinetic variability,
variation in compliance, or undisclosed dosage alteration. As a re-
sult, Allen 1983 was assessed to have a unclear risk of bias with re-
gards to other sources of bias.
By contrast, Keene 1990 described well the inclusion criteria (re-
quiring more than four seizures per month) and exclusion criteria
(no history of degenerative central nervous system disorder, brain
tumour or poor compliance) for the study. The period for which par-
ticipants were required to have suffered more than four seizures per
month, and the number of AEDs failing to control seizures, howev-
er, were not defined. Furthermore, there is no description of how
the diagnosis of epilepsy was made or the medical co-morbidities,
although the majority of included participants had some degree of
mental retardation (17/21). Whilst the dosage adjustment regimen
was comprehensively planned, no data were presented as to the
proportion of participants who required dosage amendment in this
way. Keene 1990, likewise, was deemed to have an unclear risk of
bias originating from other sources.
For the Koeppen 1987 study, doses ranged between 10 mg/day
and 40 mg/day clobazam, however, there was no clear proto-
col for dosage adjustment or standardisation of starting dose de-
scribed. In contrast to the other studies, Koeppen 1987 did specify
that epilepsy was diagnosed according to the International League
Against Epilepsy guidelines although the inclusion criteria that par-
ticipants must have at least three focal seizures a month was again
for an undisclosed period. There was no report of the methods of
recruitment, exclusion criteria or medical co-morbidities. This trial
is particularly poorly standardised between the centres with regard
to recruitment, exclusion criteria, randomisation and clobazam
dosages. Collectively, this led to us similarly awarding Koeppen
1987 an unclear risk of bias from other sources.
By comparison to the other studies, Schmidt 1986 did utilise strict
inclusion criteria. Participants had to have been attending the clinic
for at least seven years and have been diagnosed with focal epilep-
sy, according to the International Classification of Epilepsy. Par-
ticipants were defined as drug-resistant if they were still suffering
with at least three seizures per month in the year preceding the tri-
al, despite maximally tolerated doses of AED(s). Participants with
progressive brain lesions and those with impaired capacity, limit-
ing their ability to comply with treatment and record seizures accu-
rately, were excluded. No medical co-morbidities were reported in
the trial. Although the study described a slow up-titration to a max-
imal dose, it did not mention any methods for any adjustment of
dosage, dependent on patient tolerability, upon reaching the max-
imum dosage. The study was therefore, likewise, assessed to have
an unclear risk of bias with respect to other sources of bias.
E7ects of interventions
See: Summary of findings for the main comparison Clobazam
compared to Placebo in the management of drug-resistant epilep-
sy
All four studies met our inclusion criteria as they were dou-
ble-blind, randomised, placebo-controlled trials. The studies were
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all cross-over trials, however, they utilised varying clobazam doses,
varying wash-out periods between treatment arms, differing age
groups, and baseline antiepileptic drugs (AEDs), and used different
methodologies for the assessment of efficacy. Due to such method-
ological heterogeneity, as well as the unclear risk of bias associat-
ed with each study and the poor reporting of data collected, it was
not possible to perform a meta-analysis of the results. A narrative
summary of the included studies, with regard to efficacy, treatment
withdrawal, adverse events, and quality of life data, therefore fol-
lows.
FiHy per cent or greater reduction in seizure frequency
Two of the included studies, involving a total of 47 participants, re-
ported the outcome, 50% or greater reduction in seizure frequency
(Summary of findings for the main comparison),
Of the 26 participants in the study conducted by Allen 1983, 15
(57.7%) were reported as having had a 50% or greater reduction
in seizure frequency when receiving clobazam. No information was
reported regarding the number of participants who had experi-
enced a 50% or greater reduction in seizure frequency after receiv-
ing placebo. The authors did, however, perform an intention-to-
treat analysis and reported that a significantly greater proportion
of participants had a 50% or greater reduction in seizure frequency
when receiving clobazam, compared to placebo (P < 0.01). Confi-
dence intervals (95%) were not provided and there were insufficient
data in the report to allow the review authors to estimate the con-
fidence intervals or calculate the number of participants achieving
the outcome during the placebo treatment arm.
The authors of Keene 1990 reported that 11/21 participants (52.4%)
achieved a 50% or greater seizure reduction compared to baseline
during the clobazam treatment period compared to none during
the placebo period. No P value or confidence intervals were pre-
sented. Insufficient data were provided to allow us to carry out any
further analysis.
No data regarding 50% or greater reduction in seizures were de-
scribed in Koeppen 1987. The Schmidt 1986 authors did not report
data for 50% or greater reduction in seizure frequency, but they did
report that eight participants (40%) achieved 75% or greater reduc-
tion in seizure frequency. However, these data were collected on-
ly during the last month of the three-month treatment period, not
across the entire treatment period. Furthermore, it was not made
clear if comparisons were being made between treatment and pre-
treatment periods, or between the clobazam and placebo period.
Again, no information was provided about the number of partici-
pants that specifically experienced a 50% or greater reduction in
seizure frequency when receiving placebo.
The evidence implies that patients are much more likely to attain
a 50% or greater reduction in seizure frequency when receiving
clobazam than when receiving placebo. This finding is, however,
based upon the assumption that the absence of data regarding the
number of participants who achieved a 50% of greater reduction in
seizure frequency for the placebo arm meant that no participants
achieved this outcome whilst receiving placebo. Consequently, the
efficacy of clobazam has likely been overestimated.
Seizure frequency
Notably, none of the included studies separately reported the pro-
portion of participants with focal-onset seizures, or the proportion
of participants with generalised-onset seizures, that attained a 50%
or greater reduction in seizure frequency. In an attempt to address
the question of whether clobazam is equally as efficacious in man-
aging both focal and generalised epilepsy, we instead extracted the
mean seizure frequency for the two treatment arms, from the three
included studies (involving 176 participants) that reported these
data.
Allen 1983 found that mean seizure frequency was significantly low-
er during the clobazam treatment arm compared to during the
placebo treatment arm for both focal-onset seizures (with or with-
out secondary generalisation) and for all seizure types (clobazam
versus placebo: 17.5 versus 32.4 (P = 0.02) and 17.0 versus 29.9 (P
= 0.002), respectively). There was no significant difference in the
mean seizure frequency between the two treatment arms for par-
ticipants with generalised-onset seizures (clobazam versus place-
bo: 16.7 versus 24.2). The data presented for mean seizure frequen-
cy failed to include standard deviations or standard errors, hence
preventing us from undertaking any further analysis. The individ-
ual frequency of seizure types was not stated, although the mean
number of seizures per participant whilst in the placebo phase
demonstrated a higher frequency of focal-onset seizures than gen-
eralised-onset seizures (32.4 versus 24.2, respectively).
Keene 1990 did not report seizure frequency. Data allowing any fur-
ther analysis by the review authors were not reported. Whilst there
were more participants with generalised- rather than focal-onset
seizures (13 versus eight, respectively), on analysis of best respon-
ders, only those with focal seizures were significant responders
(P < 0.05). Keene 1990 stated in the text that "Patients with par-
tial seizures tended to respond better to clobazam than did those
with generalized seizures, but numbers in each seizure group were
small".
Koeppen 1987 presented the mean seizure frequency in graphical
form, no numerical data were reported. The mean seizure reduc-
tion was reported as being near to the level of significance for par-
ticipants with complex focal seizures (P = 0.06), the most prevalent
seizure type for this study, however, no other numerical data were
presented to support this. Additionally, the study did not report the
mean seizure reduction for any of the other subtypes of seizures
and, therefore, no comparison could be made.
The Schmidt 1986 authors reported that the mean number of all
seizure types during the maintenance phase (months two to three
of both treatment arms), when participants were maintained on
the full dose of clobazam or placebo, was significantly lower during
the clobazam treatment phase than the placebo phase (clobazam
versus placebo: 10.4 versus 21.5, P < 0.001). An analysis of seizure
subgroups found that mean number of focal-onset seizures (with
or without secondary generalisation) were, likewise, significant-
ly reduced (clobazam versus placebo: 10.4 versus 20.3, P < 0.01).
The results for the generalised-onset seizure group were not signif-
icant, although a 100% reduction in seizure frequency was noted
(clobazam versus placebo: 0 versus 1.1). During the whole study pe-
riod, the number of participants suffering focal-onset seizures was
greater than the number suffering generalised-onset seizures (20
versus five, respectively).
Interestingly, two of the included studies (Allen 1983; Keene 1990)
that independently assessed the efficacy of clobazam against the
seizure subtypes separately reported that clobazam significant-
ly reduced the frequency of focal-onset seizures and was inef-
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fective at significantly reducing the frequency of generalised-on-
set seizures. Likewise, the third study (Schmidt 1986) stated that
clobazam did not significantly reduce the frequency of gener-
alised-onset seizures, but, nevertheless, simultaneously reported
that clobazam produced a 100% reduction in the mean number of
generalised-onset seizures. Notably, in both studies by Allen 1983
and Schmidt 1986, a lower frequency of generalised seizures during
the placebo phase, compared to focal-onset seizures, was recog-
nised.
Overall, the general consensus appears to be that clobazam is
more efficacious at reducing focal- rather than generalised-onset
seizures, however, the slightly contradictory reports challenge and
generate uncertainty about this finding. The limited amount of da-
ta provided by the studies prevented us, the review authors, from
being able to either repeat their statistical analysis or conduct our
own meta-analysis. If possible, this would have enabled us to reach
a more conclusive finding.
Seizure freedom
Three studies, involving 175 participants, reported the outcome,
seizure freedom (Summary of findings for the main comparison).
In the study conducted by Allen 1983, three participants (11.5%)
were reported to be seizure-free during the clobazam treatment
arm. No information was provided regarding the number of partic-
ipants who were seizure-free whilst receiving placebo, and conse-
quently, again, we can only assume that no participants were.
In contrast, Koeppen 1987 reported that 20 out of the 129 (15.5%)
participants achieved seizure freedom during the clobazam arm of
the experiment and clarified that no participants were seizure-free
during the placebo arm.
Schmidt 1986 revealed that four (20%) participants were seizure-
free during treatment with clobazam. However, these data were
collected during only the last month of the three-month treatment
period, not across the entire treatment period. Again, no informa-
tion was provided about the number of participants that experi-
enced seizure freedom when receiving placebo.
Collectively, the data extracted suggest that participants are more
likely to attain seizure-freedom when receiving clobazam than
when receiving placebo. Similarly, this finding is based upon the
assumption that no participants achieved seizure-freedom whilst
receiving placebo, despite that this was not specifically declared in
two of the studies. Again, it is likely that the efficacy of clobazam
could be overestimated in this review.
Treatment withdrawal
All four studies, including 197 participants, reported treatment
withdrawal due to any reason (Summary of findings for the main
comparison).
The authors of Allen 1983 reported that six participants withdrew
from the study. One participant withdrew during treatment with
placebo for undocumented reasons. For the remaining five partici-
pants, it is assumed that they withdrew during the clobazam treat-
ment arm, however, the timing of the withdrawal and the reasons
for withdrawal are not provided.
The withdrawal data reported by Keene 1990 states that two partic-
ipants withdrew during the clobazam phase due to "severe behav-
ioural change which did not respond to lowering the drug dosage",
however, no details of these behavioural changes are documented.
In Koeppen 1987, 21 participants withdrew from treatment, of
which three leO the hospital and two withdrew for reasons not
specified. Of the remaining 16 participants, three withdrew due to
adverse events from clobazam, one due to adverse events on place-
bo, four due to insufficient efficacy of clobazam and eight due to
insufficient efficacy of placebo. Overall, 10 participants withdrew
from treatment during the clobazam arm and 11 withdrew during
the placebo arm of the study.
Schmidt 1986 reported that one participant withdrew due to "non-
compliance with seizure count and tablet count", however, the au-
thors did not confirm which treatment arm this participant was pri-
marily randomised to. As a consequence, the data are uninforma-
tive.
Overall, the evidence appears to suggest that there is only a slight-
ly increased risk of treatment withdrawal for patients receiving
clobazam, opposed to placebo.
Treatment withdrawal due to adverse events
Only two of the included studies, comprising of 150 participants,
reported this outcome (Summary of findings for the main compar-
ison).
As described earlier, Keene 1990 reported that two participants
withdrew from treatment during the clobazam arm due to "se-
vere behavioural change". In the study by Koeppen 1987, three par-
ticipants withdrew due to adverse events during treatment with
clobazam, compared to one participant withdrawing due to ad-
verse events during treatment with placebo.
The evidence is very limited due to the extremely low number of
events reported, but does suggest that patients are more likely to
withdraw from treatment, specifically as a result of adverse events,
when receiving clobazam than when receiving placebo.
Adverse events
Limited adverse events data were presented by Allen 1983 and
Keene 1990. The former study, Allen 1983, did not report any specif-
ic adverse events quantitatively, however, did state that "Adverse
effects occurred more often during the clobazam period". Specifi-
cally within the study, six participants required dose reduction due
to adverse events during the clobazam phase, compared to two
participants during the placebo phase. It was not, however, made
clear whether these participants were in addition to the six who
formally withdrew from the study. The only adverse events alluded
to were mood changes which included: irritability, depression, and
disinhibition.
Keene 1990 only acknowledged adverse events whilst describing
the withdrawal of two participants during the clobazam phase.
These withdrawals were due to "severe behavioural change which
did not respond to a lowering of the dose". No other data were pre-
sented regarding the nature or frequency of adverse events.
The authors of Koeppen 1987 report that 36% (38/106) of partic-
ipants suffered adverse events whilst on clobazam compared to
12% (13/106) on placebo. Drowsiness (71% clobazam and 16%
placebo) and dizziness (26% clobazam and 6% placebo) were the
adverse events most commonly reported. Notably, only three par-
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ticipants withdrew from the study due to adverse events, whilst on
clobazam, suggesting that the events experienced were likely mild
to moderate in severity.
A large proportion of participants reporting adverse events was
found by Schmidt 1986; 85% of participants complained of symp-
toms, mainly drowsiness (40% clobazam and 10% placebo), verti-
go (35% clobazam and 5% placebo) and depression (25% clobazam
and 5% placebo), whilst receiving clobazam. In contrast, 12 par-
ticipants (60%) reported adverse events during the placebo treat-
ment arm. It was not reported as to whether those suffering adverse
events withdrew from the trial.
Collectively, the data presented suggest that adverse events are
more frequently reported by participants when receiving clobazam
compared to placebo. It is not clear what the most common ad-
verse events were, or what the severity of these adverse events
might be, however, drowsiness was the most reported adverse
event across two of the studies.
Quality of life
Only the study conducted by Koeppen 1987, including 129 par-
ticipants, described quality of life data. Data were assessed using
the Clinical Global Impression (CGI) scale. Koeppen 1987 reported
that 60% (64/106) of participants had achieved a therapeutic effect
whilst on clobazam compared to 11% (12/106) on placebo. Further-
more, utilising three analogue scales they reported a significant im-
provement in mood state whilst in the clobazam phase (P < 0.05),
although there was also a significant increase in drowsiness (P <
0.05). There was, however, no explanation of the methods used to
collect and analyse these data and, notably, an intent-to-treat pop-
ulation was not used for this analysis.
Tolerance
The only study to attempt an assessment of tolerance was that con-
ducted by Allen 1983 who, whilst reporting evidence of no toler-
ance, only attempted to assess this by comparison between the
first and last four weeks of the treatment period, using a method
that was not described.
In contrast, despite that neither Keene 1990 or Schmidt 1986 men-
tioned a formal assessment of tolerance, both studies reported that
participants developed a tolerance to the antiepileptic effects of
clobazam. Keene 1990 did not report the exact number of partic-
ipants who developed tolerance but did state that it was "a sig-
nificant number of patients", adding later that the tolerance re-
ported, however, remained "much less frequent than that report-
ed in the literature". Meanwhile, Schmidt 1986 specified that four
of nine participants developed tolerance within the three-month
treatment period.
Due to the lack of specific details provided by the studies, with re-
gards to the methodology and the exact number of participants
concerned, it is difficult to reach an overall judgement on the like-
lihood of patients developing tolerance after receiving clobazam.
D I S C U S S I O N
Summary of main results
Four studies, representing 197 randomised participants, met the in-
clusion criteria for this review. All of the studies were randomised,
double-blind, placebo-controlled, cross-over trials with two treat-
ment periods. The reporting of important methodological factors,
such as the method of randomisation and blinding, was poor. As
a result, all of the included studies were judged to be at unclear
risk of bias. Due to differences in the study methodology, the choice
of outcomes, and the inadequate reporting of outcome data, it
was not possible to summarise data in a meta-analysis and, conse-
quently, we have summarised data in narrative form for this review.
The majority of participants recruited into three of the four stud-
ies had focal-onset seizures and, between them, the included stud-
ies tested a range of clobazam doses (as summarised in the Char-
acteristics of included studies table). Current data suggest that, for
patients with drug-resistant epilepsy, clobazam, when used as an
add-on treatment, may reduce the frequency of seizures, although
it was not possible to quantify precisely the treatment effect. More-
over, the evidence gathered by this review suggests that clobazam
may be more efficacious in the management of focal epilepsy
rather than generalised epilepsy. Adverse-events rates were high-
er during clobazam treatment periods, particularly for drowsiness,
but current data did not precisely define the adverse-events pro-
file of clobazam, nor the precise risk of individual adverse events. A
slightly increased treatment withdrawal rate for participants when
receiving clobazam was noted, including treatment withdrawal
specifically due to adverse events. The development of tolerance
to the antiepileptic effects of clobazam amongst participants was
described in three of the included studies, however, no data were
presented to support these observations. Importantly, the impact
of clobazam on quality of life was not adequately assessed by the
included studies either.
Overall, this review does suggest that clobazam could be beneficial
to patients with drug-resistant epilepsy when utilised as an add-on
therapy, however, we have not been able to generate an estimate
of clobazam's efficacy or tolerability. Additionally, and most impor-
tantly, we are very uncertain that the effect that we have reported
is accurate of the true efficacy of clobazam as a result of the low
number of studies included in this review and the very low quali-
ty of evidence that they provided (See Summary of findings for the
main comparison). This equally applies to the observations made
regarding the tolerability of clobazam.
Overall completeness and applicability of evidence
We were unable to conduct a meta-analysis on the included studies
as a result of methodological heterogeneity, the unclear risk of bias
across studies, and the inconsistency of data reporting within the
studies. Consequently, our ability to answer the original question,
is clobazam an effective add-on therapy for drug-resistant gener-
alised-onset and focal-onset seizures, with or without secondary
generalisation, in adults and children, is limited. The narrative sum-
mary presented here does suggest that clobazam is effective at
treating drug-resistant focal epilepsy and lacks efficacy for gener-
alised epilepsy. This finding is, however, confounded by the limit-
ed number of participants with generalised epilepsy, recruited to
the studies. Similarly, we are unable to infer whether clobazam is
equally as efficacious at managing drug-resistant focal epilepsy in
both adults and children because only one study, Keene 1990, in-
cluded participants under the age of 18.
Within the included studies, the lack of consistency and detail in
the reporting of study methods and results was recognised. This
likely reflects the age of the studies as all four were conducted in
the previous century. More recently, there has been a large focus
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placed on the need for data dissemination, with respect to clinical
trials, regarding both their methodology, their outcome findings,
and their patient demographic (Brunoni 2010; Hudson 2015). The
age of the included studies thus impacts our ability to make con-
clusions about the efficacy and tolerability of clobazam.
Quality of the evidence
All four studies were assessed to have an unclear risk of bias, large-
ly owing to the insufficient amount of information available on
the methods used by each study. Specifically, all four of the in-
cluded studies failed to describe the methods used for random
sequence generation and allocation concealment. We are, there-
fore, unsure whether selection bias might exist within the popu-
lations randomised to the first cross-over arm of each study. The
unclear risk of bias across the studies is reflected in the GRADE
assessment (See Summary of findings for the main comparison).
Although the results reported were fairly consistent between the
studies, and were well-directed to answer the original objective of
the review, the narrative synthesis of the data produced impreci-
sion in the analyses which negatively impacted the overall GRADE
assessment. This collectively led to the quality of evidence being
judged as very low for all four of the analysed outcomes. As a result,
we are very uncertain about the accuracy of the effects observed
and reported here.
Potential biases in the review process
Although, in accordance with our protocol, we have requested the
trial protocols corresponding to each of the included studies, the
time lag between when the review has been conducted compared
to the time at which the original studies took place means that it has
been very difficult to acquire any additional documents or missing
data. This has, thus, greatly impacted our ability to conduct the re-
view.
Agreements and disagreements with other studies or
reviews
Other reviews, namely Robertson 1995 and Remy 1994, have sim-
ilarly highlighted the increased efficacy of clobazam over place-
bo in managing epilepsy. Although both reviews included patients
that were receiving clobazam as a monotherapy, the majority of pa-
tients were using clobazam as an add-on for polytherapy. Both re-
views agreed that the main clinical indication for clobazam is as an
add-on for the management of drug-resistant epilepsy, the focus of
our current review.
Interestingly, both reviews demonstrated that the efficacy of
clobazam is not just restricted to its short-term use, but is also
observed after continued, long-term use, despite the concerns re-
garding tolerance. Both studies did, however, state that the inci-
dence of tolerance amongst patients is highly variable between
studies, consistent with that noted here in this review. Robertson
1995 and Remy 1994 reported that on average, 32% and 39% of
patients, respectively, develop tolerance whilst receiving clobazam
long term. Remy 1994 specified that tolerance usually occurs with-
in one to six months of initiating treatment, and most commonly
develops at six months. This thus emphasises that the short-term
follow-up periods, characteristic of the included studies for this re-
view, are most likely insufficient in length for tolerance to be ob-
served. Consequently, this could lead us to underestimate the in-
cidence of tolerance. A larger-scale, longer-term study is therefore
necessary to fully determine the risk of tolerance amongst patients.
Remy 1994, nevertheless, reported that 28% of patients, almost
one in three, can achieve long-term control of their epilepsy, us-
ing clobazam, without experiencing any diminished effectiveness
or developing tolerance. Three reviews considered clobazam to be
a tolerable drug (Montenegro 2003; Remy 1994; Robertson 1995).
In agreement with our findings in this review, the most commonly
reported adverse event was sedation, including drowsiness (Remy
1994; Robertson 1995). Notably, all of the reviews referenced were
conducted prior to the millennium and, therefore, similar to this re-
view, their literature base is limited to older clinical studies.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For patients with drug-resistant epilepsy, clobazam when used as
an add-on treatment may potentially reduce seizure frequency but
we are very uncertain about this conclusion. There are more data
to support this for patients with focal-onset seizures than for pa-
tients with generalised-onset seizures. The quality of existing da-
ta is very low and it is not possible to define the size of treatment
effect. The adverse events most commonly reported were drowsi-
ness, dizziness, and vertigo, but current data do not adequately de-
fine the adverse-event profile of clobazam. Of importance, we must
stress that the very low quality of evidence means that we are very
uncertain about whether the effects described here are accurate of
the true effectiveness and tolerability of clobazam.
Implications for research
To better inform clinical practice, we require various large-scale,
multi-centre, parallel-group, randomised, controlled trials com-
paring clobazam with placebo, as well as other add-on treatments,
for patients with drug-resistant epilepsy. Future trials should re-
cruit a heterogeneous population with well-defined seizure and
epilepsy types to allow the identification of patient factors, such
as age, pathology, seizure types, and baseline antiepileptic drugs
(AEDs), associated with the greatest benefit or harm. Of interest, re-
search is increasingly being undertaken into epilepsy genetics, with
regard to the factors contributing to 'drug-resistant' epilepsy and
identifying for whom which particular AEDs will achieve greatest ef-
ficacy. Such investigations could potentially be included in future
research into clobazam. Additionally, longer-term studies are nec-
essary to fully assess the incidence of tolerance amongst patients.
Of particular note for clinical practice, because it has been oG-
patent for over 20 years, clobazam is cheaper than the newer AEDs
available for use as add-on treatments for drug-resistant epilepsy.
None of the studies included in this review, however, assessed cost-
effectiveness, evaluation of which would need to be undertaken in
any future research to inform clinical practice.
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Characteristics of included studies [ordered by study ID]
 
Methods Study design: double-blind, randomised, placebo-controlled, cross-over study (1 centre, UK)
Treatment period per arm: 9 weeks
Washout period: 8 weeks
Participants Randomised population: 26 patients
Age mean (range): 34 (18 to 60) years
Seizure type: drug-resistant focal-onset seizures (with or without secondary generalisation) and gen-
eralised-onset seizures
Allen 1983 
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Interventions 30 mg/day clobazam nightly
Placebo nightly
Outcomes Primary outcome
1. Overall reduction in seizure frequency
Secondary outcomes
1. Reduction in generalised seizures frequency (calculated from mean number of seizure types per
group rather than seizures per individual)
2. Reduction in focal-onset seizures frequency
3. Proportion with > 50% reduction in seizures
4. Proportion seizure free
Safety and tolerability outcomes
1. Drug tolerance
2. Adverse events
Notes Data for the first and second periods of the cross-over trial were not reported separately.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no information provided.
Allocation concealment
(selection bias)
Unclear risk Comment: no information provided.
Blinding (performance
bias and detection bias) 
All outcomes





Low risk Quote: "identically matched placebo capsule"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "identically matched placebo capsule"
Comment: participants would have self-reported seizure frequency and there-
fore acted as the outcome assessors. Study personnel would also have been




Low risk Comment: attrition was reported. Additional analysis was conducted in which
patients who withdrew from treatment were included and were assumed to be
non-responders, consistent with intention-to-treat.
Selective reporting (re-
porting bias)
Unclear risk Comment: no protocol was available. No outcome measures were predefined
prior to the reporting of the outcome results
Allen 1983  (Continued)
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Other bias Unclear risk Comment: undetailed report lacks specific information on diagnosis of epilep-





Methods Study design: double-blind, randomised, placebo-controlled, cross-over study
Baseline period: 4 weeks
Treatment period per arm: 12 weeks
Washout period: 4 weeks
Participants Randomised population: 21 patients
Age mean (range): 11 (2 to 19) years
Gender: 10 males and 11 females
Seizure type: drug-resistant generalised-onset seizures (13 participants), focal-onset seizures (8 partic-
ipants)
Interventions 0.25 mg/kg/day to 1 mg/kg/day clobazam
Placebo
Outcomes Primary outcomes
1. Proportion with > 50% reduction in seizure frequency overall
Safety and tolerability outcome
1. Laboratory tests
2. EEG recordings
Notes Data for the first and second periods of the cross-over trial were not reported separately.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: information on the randomisation method was not provided
Allocation concealment
(selection bias)
Low risk Quote: "patients were randomly assigned into the placebo or the trial drug
group. This was done by the hospital pharmacy without the patient, physi-
cian or dispensing pharmacist being aware of which group the patient had en-
tered."
Blinding (performance
bias and detection bias) 
All outcomes





Unclear risk Comment: no information on the method of blinding was provided
Keene 1990 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: attrition was reported. All randomised patients were included in




Unclear risk Comment: no protocol was available. Only one efficacy outcome was defined
in the methods and reported in the results. We suspect that more outcomes,
including safety outcomes such as adverse events, were measured but were
not reported.
Other bias Unclear risk Comment: no description of how the diagnosis of epilepsy was made. No da-
ta provided regarding the participants who required dosage amendment al-




Methods Study design: multicentre, double-blind, randomised, placebo-controlled, cross-over study (Belgium,
France, Germany, Italy and Spain)
Baseline: 4 weeks
Treatment period per arm: 12 weeks (4 weeks titration and 8 weeks maintenance)
Washout period: 4 weeks
Participants Randomised population: 129 patients
Age mean ± SD: 33 ±12 years
Gender: 56 males and 73 females
Seizure type: mainly drug-resistant focal-onset seizures
Interventions 10 mg to 40 mg/day clobazam (single daily dose tablet taken in the evening)
Placebo (single daily dose tablet taken in the evening)
Outcomes Primary Outcome
1. Seizure frequency
Safety and tolerability outcomes
1. EEG ratings




Notes Data for the first and second periods of the cross-over trial were not reported separately.
Risk of bias
Koeppen 1987 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no information on the method of randomisation was provided
Allocation concealment
(selection bias)
Unclear risk Comment: no information on the method of allocation concealment was pro-
vided
Blinding (performance
bias and detection bias) 
All outcomes





Unclear risk Comment: no information on the method of blinding was provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Comment: no protocol was available. Outcomes were not clearly defined in
the methods section so it is unclear whether the outcomes were sufficiently re-
ported.
Other bias Unclear risk Comment: methodology varied between centres and was not standardised. No
description of exclusion criteria was reported and the description of dose es-




Methods Study design: double-blind, randomised, placebo-controlled, cross-over study
Baseline:
Treatment period per arm: 12 weeks (4 weeks titration + 8 weeks maintenance)
Transition period: 4 weeks (drug 1 gradually down-titrated whilst drug 2 concomitantly up-titrated)
Participants Randomised population: 21 patients
Age mean (range): 38 (18 to 54) years
Gender: 9 males and 11 females
Seizure type: drug-resistant focal-onset seizures (complex and simple focal-onset, generalised ton-
ic-clonic seizures)
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Safety and tolerability outcomes
1. Adverse events
2. Vital signs
3. Routine clinical chemistry studies
4. Neurological and psychiatric examinations
Notes Data for the first and second periods of the cross-over trial were not reported separately.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no information on the method of randomisation was provided
Allocation concealment
(selection bias)
Unclear risk Comment: no information on the method of allocation concealment was pro-
vided
Blinding (performance
bias and detection bias) 
All outcomes





Low risk Quote: "The placebos were matched in color, size and taste."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: patients self-reported seizure frequency and adverse events,
thus acting as the outcome assessors. Patients were effectively blinded by
matching placebo. Study personnel would also be sufficiently blinded by the





Unclear risk Comment: one patient was excluded due to noncompliance therefore attrition
was reported. Intention-to-treat analysis was not performed.
Selective reporting (re-
porting bias)
Unclear risk Comment: protocol was not available. Specific outcome measures were not
defined in the methods so cannot ascertain whether outcome measures are
fully reported in the results section.






Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Andrade 2009 This study is not applicable as clobazam was used as monotherapy and not as add-on treatment.
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Study Reason for exclusion
Basu 2007 This is an open-label, unblinded trial so not applicable for inclusion.
Conry 2009 This study did not have the required 8-week standard treatment period that we stated in the pro-
tocol. Also this is a specific subtype of childhood epilepsy (Lennox-Gastaut) associated with signifi-
cant cognitive impairment; it makes up < 5% of childhood epilepsies and is a very different entity.
NCT02134366 This study was prematurely terminated and no results are available for the study.
NCT02564952 This is an open-label extension study, unblinded trial with no control group so not applicable for in-
clusion.
NCT02565108 Both treatment groups received clobazam. The intervention group received clobazam and
cannabidiol and the control group received clobazam and placebo. The study was therefore not eli-
gible for inclusion.
NCT02726919 This is an open-label extension study, unblinded trial with no control group so was not applicable
for inclusion
Semah 2014 This study is an open-label, cluster-randomised trial in patients with persistent focal seizures de-
spite treatment with one AED. Only 3 patients received clobazam as add on treatment.
Vajda 1985 Pilot study with only a 3-day treatment period, followed by a longer-term study of 4 weeks, with no
wash-out period. Only 9 participants randomised (of which 4 were later transferred to the open tri-
al) and only preliminary results presented, incorporating open, non-randomised participants. No
standard follow-up period or outcome measures. For the 5 in the randomised phase, no data pre-




A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. (clobazam* OR frisium OR urbanol OR urbanyl OR onfi):AB,KW,MC,MH,TI AND CENTRAL:TARGET
2. (monotherap* NOT (adjunct* OR "add-on" OR "add on" OR adjuvant* OR combination* OR polytherap*)):TI AND CENTRAL:TARGET
3. #1 NOT #2
4. #3 AND >25/04/2016:CRSCREATED
Appendix 2. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials, published in Lefebvre 2011.
1. (clobazam$ or frisium or urbanol or urbanyl or onfi).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
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8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or "add-on" or "add on" or adjuvant$ or combination$ or polytherap$)).ti.
16. 14 not 15
17. remove duplicates from 16
18. limit 17 to ed=20160425-20181009
19. 17 not (1$ or 2$).ed.
20. 19 and (2016$ or 2017$ or 2018$).dt.
21. 18 or 20
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | clobazam OR frisium OR urbanol OR urbanyl OR onfi | First posted from 04/25/2016 to 10/09/2018
Appendix 4. ICTRP search strategy
Condition: epilepsy
Intervention: clobazam OR frisium OR urbanol OR urbanyl OR onfi
Recruitment status: all
Date of registration between 25/04/2016 and 09/10/2018
Appendix 5. Original search methods for identification of studies
We searched the following databases, on 22 March 2007, for randomised trials using the search terms 'clobazam', 'seizure' and 'epilepsy'.
1. The Cochrane Epilepsy Group Specialised Register (22 March 2007)
2. The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 2)
3. MEDLINE (all prior to 22 March 2007)
4. Embase (all prior to 22 March 2007)
5. Database of Abstracts of Reviews of Effectiveness (DARE) (22 March 2007)
6. American College of Physicians Journals (22 March 2007)
7. BIOSIS (22 March 2007)
In addition we handsearched reference lists from identified trials for other relevant articles.
W H A T ' S   N E W
 
Date Event Description
9 October 2018 New citation required but conclusions
have not changed
Conclusions are unchanged
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Date Event Description
9 October 2018 New search has been performed Searches updated 9 October 2018; no new studies identified for
inclusion
 
H I S T O R Y
Protocol first published: Issue 4, 2007
Review first published: Issue 2, 2008
 
Date Event Description
2 February 2011 New search has been performed Searches updated 2 February 2011; no new studies identified for
inclusion.
2 February 2011 New citation required but conclusions
have not changed
Review updated: conclusions remain unchanged.
 
C O N T R I B U T I O N S   O F   A U T H O R S
R. Bresnahan: systematic review of studies identified following updated search (April 2016 - October 2018) and the conduct of this review
update.
K. Martin-McGill: systematic review of studies identified following updated search (April 2016 - October 2018)
J. Williamson: systematic review of studies identified following updated search (November 2012 - April 2016) and the initial conduct of
this review update.
B. Michael: systematic review of studies included in the original version of the review and composition of the original document (Michael
2008). Systematic review of studies identified following updated search (November 2012 - April 2016).
A. Marson: systematic review of studies and editing of final document in original review (Michael 2008).
D E C L A R A T I O N S   O F   I N T E R E S T
R. Bresnahan: none known.
K. Martin-McGill: none known.
J. Williamson: none known.
B. Michael: none known.
A. Marson: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in
Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for Health
Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
This review update was supported by the National Institute for Health Research, via Cochrane Programme Grant funding to the Epilepsy
Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The protocol specified that trials with any level of blinding (double-blind, single-blind or unblinded) were eligible for inclusion in this
review. However, in accordance with the methods of the previously published version of this review, by Michael 2008, we judged that only
double-blind studies were eligible for inclusion. The original review protocol also stated that only participants with focal-onset seizures
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should be included. This inclusion criteria was, however, expanded to also include participants with generalised-onset seizures in the
previously published version of this review (Michael 2008). Again, for the purposes of the review update, we followed the methods specified
by Michael 2008, and continued to include studies that contained both participants with focal- and generalised-onset seizures.
Furthermore, in contrast to the review protocol, we included the additional efficacy outcome, mean seizure reduction, Notably, none of the
included studies reported the specific proportion of participants with focal-onset seizures or the specific proportion of participants with
generalised-onset seizures that attained a 50% or greater reduction in seizure frequency, the outcome which we had originally intended
to extract. Three of the studies, however, reported mean seizure reduction for both participants with focal-onset and generalised-onset
seizures, separately. Including this additional efficacy outcome enabled us to examine whether clobazam was equally as efficacious at
managing focal and generalised epilepsy.
Additionally, we altered the order of the outcomes listed in the original protocol. Notably, the protocol suggested that treatment with-
drawal should be reported first, which would imply that this was the primary outcome. Instead, we reported 50% or greater seizure reduc-
tion first because this is the primary measure of efficacy and is the more important outcome that clinicians and end users would most
likely be interested in. Additionally, this method of reporting, i.e. reporting efficacy outcomes prior to reporting tolerability outcomes, is
more consistent with other current Cochrane Reviews.
Finally, we made small alterations to the wording of the original methods, adapted from the protocol by Michael 2007, and changed the
previously suggested method for data synthesis from Peto odds ratio to Mantel-Haenszel risk ratio. All of the amendments made were to
ensure that the review remained consistent with the guidelines detailed in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). The amendment of the data synthesis method from Peto odds ratio to Mantel-Haenszel risk ratio was especially important
to aid the consumer's understanding of the reported findings as odds ratio is commonly misunderstood.
The term 'partial' has been replaced by 'focal', in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (Scheffer 2017).
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants  [administration & dosage]  [*therapeutic use];  Benzodiazepines  [administration & dosage]  [*therapeutic use];  Clobazam;
  Epilepsy  [*drug therapy];  Randomized Controlled Trials as Topic
MeSH check words
Humans
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